Paper Details

  1. Home
  2. Paper Details

Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress.

Author: BrunialtiMilena Karina Coló, KohIvan Hong Jun, LiberatoreAna Maria Alvim, MartinsVanessa, RodriguesLarissa de Oliveira Cavalcanti Peres, SalomãoReinaldo, SantosSidneia Sousa, SorianoFrancisco Garcia, SzaboCsaba

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Olaparib, a PARP1 inhibitor, is clinically used to treat various diseases, including sepsis. This study assessed the effects of olaparib on human peripheral blood leukocytes challenged with bacteria, LPS, or oxidative stress. Olaparib did not negatively impact lymphocyte viability or hinder pathogen eradication, but it exerted cytoprotective effects and modulated inflammatory cytokine production. The findings suggest olaparib may be a potential experimental therapy for septic shock.
Paper Details　
Original Abstract of the Article :
Prior studies demonstrate the activation of poly-(ADP-ribose) polymerase 1 (PARP1) in various pathophysiological conditions, including sepsis. We have assessed the effect of olaparib, a clinically used PARP1 inhibitor, on the responses of human peripheral blood leukocytes (PBMCs) obtained from healt...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221060/

データ提供：米国国立医学図書館（NLM）

Olaparib: A Potential Life Raft in the Storm of Sepsis?

Sepsis, a life-threatening condition caused by a dysregulated immune response to infection, remains a major health concern. This research, a journey through the desert of sepsis research, explores the potential of olaparib, a PARP inhibitor used in cancer treatment, as a potential therapy for septic shock.

A New Direction: Repurposing Olaparib for Sepsis

Researchers investigated the effects of olaparib on human peripheral blood leukocytes (PBMCs) in response to bacterial challenge and oxidative stress. This study, like a careful examination of a desert oasis's ecosystem, sought to understand the impact of olaparib on the immune response in sepsis.

Promising Results: A Glimpse of Protection

The study revealed that olaparib exhibited cytoprotective effects, mitigating the detrimental effects of bacterial challenge and oxidative stress on PBMCs. It also modulated inflammatory cytokine production without impairing the cells' ability to fight infection. These findings suggest that olaparib may hold promise as a potential therapeutic agent for septic shock.

Health Implications and Everyday Life: A Potential Life Raft in the Desert

This research, a beacon of hope in the desert of sepsis research, highlights the potential of olaparib as a repurposed therapy for septic shock. For individuals at risk of sepsis or those experiencing this life-threatening condition, this research offers a glimmer of optimism for new treatment strategies that could improve patient outcomes.

Dr. Camel's Conclusion

This research, a compelling exploration in the desert of sepsis research, showcases the potential of olaparib as a novel therapy for septic shock. The findings suggest that olaparib, through its cytoprotective effects and modulation of inflammation, may offer a potential therapeutic avenue for improving patient outcomes in this life-threatening condition.

Date :
  1. Date Completed 2022-06-27
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

35740913

DOI: Digital Object Identifier

PMC9221060

Related Literature

Article Analysis
・Effects of olaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.